Company news

Cytokinetics, Incorporated news in 2022

Cytokinetics, Incorporated's news releases, calls and decks from 2022, newest first.

View company

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

December 12, 2022

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

December 8, 2022

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

December 7, 2022

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

December 6, 2022

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

November 30, 2022

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

November 6, 2022

Cytokinetics Reports Third Quarter 2022 Financial Results

November 2, 2022

Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022

October 30, 2022

Cytokinetics to Announce Third Quarter Results on November 3, 2022

October 19, 2022

Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

October 9, 2022

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

September 27, 2022

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

September 25, 2022

Cytokinetics Reports Second Quarter 2022 Financial Results

August 3, 2022

Cytokinetics to Announce Second Quarter Results on August 4, 2022

July 20, 2022

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

June 30, 2022

Cytokinetics Announces Proposed Convertible Senior Notes Offering

June 28, 2022

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

June 23, 2022

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

June 16, 2022

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

June 15, 2022

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

June 12, 2022

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

June 2, 2022

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

May 22, 2022

Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

May 16, 2022

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress

May 15, 2022

Cytokinetics Reports First Quarter 2022 Financial Results

May 3, 2022

Cytokinetics to Announce First Quarter Results on May 4, 2022

April 19, 2022

Cytokinetics Announces Changes to Board of Directors

April 7, 2022

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

April 2, 2022

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session

April 1, 2022

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo

March 23, 2022

Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment

March 1, 2022

Cytokinetics Reports Fourth Quarter 2021 Financial Results

February 23, 2022

Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

February 22, 2022

Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease

February 15, 2022

Cytokinetics Announces Topline Results From METEORIC-HF

February 14, 2022

Cytokinetics to Announce Fourth Quarter Results on February 24, 2022

February 9, 2022

Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction

February 3, 2022

Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM

January 31, 2022

Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants

January 23, 2022

Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

January 6, 2022

Calls in 2022

Decks in 2022